About Connext
Connext is a company founded in 2017. It operates as a HealthTech, and Licensing Model. Connext offers products and services including CNT101 (Recombinant TLR5 Agonist) and CNT201 (Recombinant Collagenase). Connext operates in a competitive market with competitors including Moderna, BridgeBio, BeiGene, Spark Therapeutics and Rhythm Pharmaceuticals, among others.
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Connext Co., Ltd.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Connext
Connext offers a comprehensive portfolio of products and services, including CNT101 (Recombinant TLR5 Agonist) and CNT201 (Recombinant Collagenase). The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Developed to prevent side effects in cancer treatments.
Designed to treat Dupuytren's contracture and related conditions.
Funding Insights of Connext
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Connext
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Connext
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Connext Comparisons
Competitors of Connext
Connext operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, BeiGene, Spark Therapeutics and Rhythm Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Connext
When was Connext founded?
Connext was founded in 2017.
Who is the current CEO of Connext?
Woo-Jong Lee is the current CEO of Connext.
What does Connext do?
Connext, a clinical-stage bioventure, is focused on the development of biopharmaceuticals aimed at enhancing quality of life. Innovative drugs are being developed to prevent side effects from cancer and radiation therapies using recombinant TLR5 agonist technology. Additionally, the worlds first recombinant collagenase treatment is under development for conditions like Dupuytrens contracture. The company is expanding its pipeline in immuno-oncology and regenerative medicine sectors. Efforts are made to introduce, develop, and commercialize cutting-edge biotechnologies for global health impact.
Who are the top competitors of Connext?
Connext's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Connext offer?
Connext offers CNT101 (Recombinant TLR5 Agonist) and CNT201 (Recombinant Collagenase).
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.